{"name":"Glia, LLC","slug":"glia-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CLM2 topical gel","genericName":"CLM2 topical gel","slug":"clm2-topical-gel","indication":"Pain relief for musculoskeletal conditions","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"GL101","genericName":"GL101","slug":"gl101","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"CLM2 topical gel","genericName":"CLM2 topical gel","slug":"clm2-topical-gel","phase":"phase_2","mechanism":"CLM2 topical gel is a treatment for pain relief by targeting the underlying cause of pain.","indications":["Pain relief for musculoskeletal conditions"],"catalyst":""},{"name":"GL101","genericName":"GL101","slug":"gl101","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQamJ0QmVzNTRYNTJrSVFsVk9iS0RaaUZpcGVVRHljcVJ3QkZ4SXpBcnRVX2lHdnVodFIweHZOMXQ5SG94WVUwcm5zenVQb0gzWXlQc2FnVDR5SmozOEpQQlBJblZqWS12SmVVOGtJekdJX1RBM1o3WjF1UjJ0VUxCMy0zUlZKbEl3a2dtNng1QmlEUUwwSVEybUJOX0xBeW90SjJXMHFYZm1SYXFFSDMzdlZKZWEta0JFQVMwaVpQUFJSODEtdFFXczBWdUIxclJ0VzV6OFQ2WQ?oc=5","date":"2024-08-14","type":"trial","source":"Healio","summary":"Signal12 readies phase 3 trials for transappendageal forehead delivery of dry eye therapy - Healio","headline":"Signal12 readies phase 3 trials for transappendageal forehead delivery of dry eye therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxNVU5hLTJ4cE1hcnh5RDlIdHVwcGlFbzVYai1nZFdCd19LRTZwUGw4Nm5WdkthTU9xdWZ3aHI5LWdUQ1ZZdDJNOEp2NUFBeGZxNGJ2cm11dFU0VDQyLVRSS0p0Z1RyOEZlUUtpMktFVjd1WlVsOG9lX2phTDVmUF9fa2NQTnZaZXdHR05xTmNXVU1pWnU2blVldmM4U2RKZUpzY1ZxblZwNW9GX2tNc2dtVFpRY2I3WVU3MWk3Snlsc3dVT2NMUWJ3empsRm96bVZMbjRNVEg4YVJxekYxSU02R0ZRek1ZeVUzM2lfOGl4S1NNMGF1eFJoMDhDWHB2YlR3aE12T2ozb2JaQVV2ZHVGVQ?oc=5","date":"2024-08-13","type":"pipeline","source":"prnewswire.com","summary":"Spencer Trask & Co. Launches Dry Eye Venture Signal12 with Former Aerie Pharmaceutical Executives Thomas Mitro and Marvin Garrett - prnewswire.com","headline":"Spencer Trask & Co. Launches Dry Eye Venture Signal12 with Former Aerie Pharmaceutical Executives Thomas Mitro and Marvi","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}